GX-03

COMBINATION_PRODUCT2 trials

Sponsors

Turn Therapeutics

Conditions

Atopic DermatitisCovid19EczemaEczema Atopic Dermatitis

Phase 2

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

CompletedNCT04951349

Turn TherapeuticsCovid19

Start: 2021-01-21End: 2021-05-30Updated: 2021-07-06

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

RecruitingNCT07355075

Turn TherapeuticsAtopic Dermatitis, Eczema, Eczema Atopic Dermatitis

Start: 2025-07-11End: 2026-07-10Target: 110Updated: 2026-05-18